The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: (link sends e-mail)

Study Name on (link is external)
A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis (SMR-2984)
Study Drugalginate oligosaccharide
Type of Study DrugMucus Alteration
Study TitleA double-blind, randomised, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis.
Study Phase2b
Study SponsorAlgipharma

Link on (link is external) (link is external)

Participating ECFS-CTN sitesDenmark: Copenhagen
Germany: Berlin, Frankfurt, Hannover, Cologne, Munchen
Sweden: Gothenburg, Stockholm
UK: Belfast, London, Nottingham
Age18 years and older